Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the Guggenheim 4th Annual Immunology and Neurology Day on November 14-15, 2022.

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the Guggenheim 4th Annual Immunology and Neurology Day on November 14-15, 2022. Raj Mehra, Ph.D., Chairman and CEO, is scheduled for 1x1 investor meetings and a presentation on November 15 at 1:35 PM ET. The company specializes in developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions such as Major Depressive Disorder, ALS, and Parkinson's disease. For more details, visit seelostherapeutics.com.

Argus Session date unavailable

-0.84% session move Open Argus

Details

News Market Reaction – SEEL

The recorded move for SEEL in the trading session of this news was -0.84%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Nov. 7, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim 4^th Annual Immunology and Neurology Day, November 14^th and 15^th.

Raj Mehra, Ph.D., Chairman and CEO will hold 1x1 investor meetings and present on Tuesday, November 15^th at 1:35pm ET. 

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2^nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer 
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-guggenheim-4th-annual-immunology-and-neurology-day-301670562.html

SOURCE Seelos Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Seelos Therapeutics participating in the Guggenheim 4th Annual Immunology and Neurology Day?

Seelos Therapeutics will participate on November 14 and 15, 2022.

Who will represent Seelos Therapeutics at the Guggenheim event?

Raj Mehra, Ph.D., Chairman and CEO, will represent Seelos Therapeutics.

What time is Seelos Therapeutics' presentation at the Guggenheim event?

The presentation is scheduled for November 15, 2022, at 1:35 PM ET.

What is Seelos Therapeutics focused on developing?

Seelos Therapeutics is focused on developing therapies for central nervous system disorders and rare diseases.

What conditions does Seelos Therapeutics' portfolio address?

The portfolio targets conditions like Major Depressive Disorder, ALS, and Parkinson's disease.